The Native Antigen Company launches new Bordetella pertussis toxin
The Native Antigen Company, contract service provider to the in vitro diagnostics industry based in Oxford, UK, has launched a new purified Bordetella pertussis toxin.
The Native Antigen Company, contract service provider to the in vitro diagnostics industry based in Oxford, UK, has launched a new purified Bordetella pertussis toxin.
The toxin was developed in response to the increasing pressure on the in vitro diagnostics industry to supply highly specific, cost-effective antibody capture systems, which are needed to monitor vaccination programmes.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Recognised with 2025 Excellence Awards for Research and Development and Marketing, Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.
